Paxlovid Pharmacist Survey
|
The following information has been shared on behalf of the Ministry of Health |
Pharmacists are invited to take this short survey about assessing, dispensing and monitoring adverse events of nirmatrelvir/ritonavir (Paxlovid). Pharmacists are eligible to claim fees for clinical assessment (PAX-A) and for follow-up and monitoring of patients who received Paxlovid (PAX-F). Your input will help us evaluate this service and may be used to inform future initiatives.
This survey will take about 5 minutes to complete.
Take the Survey
The survey closes on, December 31, 2022